# AM-101 in the Treatment of Post-Acute Tinnitus 2

> **NCT02040207** · PHASE3 · COMPLETED · sponsor: **Auris Medical AG** · enrollment: 487 (actual)

## Conditions studied

- Tinnitus

## Interventions

- **DRUG:** AM-101

## Key facts

- **NCT ID:** NCT02040207
- **Lead sponsor:** Auris Medical AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 487 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040207, "AM-101 in the Treatment of Post-Acute Tinnitus 2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02040207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*